3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neoplasms
3
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Breast Neoplasms
2
Urologic Neoplasms
1
Thyroid Neoplasms
1
Soft Tissue Neoplasms
1
Sarcoma
1
Rhabdomyosarcoma, Embryonal
1
Rhabdomyosarcoma, Alveolar
1
Rhabdomyosarcoma
1
Recurrence
1
Pharyngeal Neoplasms
1
Patients With Advanced or Metastatic Solid Tumors
1
PRETEXT I Hepatoblastoma
1
Neurofibromatosis 2
1
Neoplasms, Mesothelial
1
Mouth Neoplasms
1
Melanoma
1
Lymphangioleiomyomatosis
1
Lung Neoplasms
1
Kidney Neoplasms
1
Glioma
1
Glioblastoma
1
Erdheim-Chester Disease
1
Endometrial Adenocarcinoma
1
Endocrine Gland Neoplasms
1
Colonic Neoplasms
1
Castleman Disease
1
Interventions
Imatinib Mesylate
6
Sunitinib
4
ripretinib
2
regorafenib
2
Specimen Handling
2
Paclitaxel
2
Magnetic Resonance Spectroscopy
2
IDRX-42
2
trastuzumab deruxtecan
1
pemigatinib
1
olverembatinib
1
envafolimab
1
atezolizumab
1
apatinib
1
Temozolomide
1
Surgical Instruments
1
Sorafenib
1
Rogaratinib
1
Nivolumab
1
Midazolam
1
Laparoscopy
1
Ipilimumab
1
Cyclophosphamide
1
CTLA-4 Antigen
1
Blood Specimen Collection
1
Biopsy
1
4-Aminopyridine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastrointestinal Stromal Tumors
×
temsirolimus
×
90 days
×
Clear all
No trials found.